

U.S. DEPARTMENT OF AGRICULTURE  
ANIMAL AND PLANT HEALTH INSPECTION SERVICE  
BIOTECHNOLOGY REGULATORY SERVICES  
**BRS NOTIFICATION - INTRODUCTION OF GENETICALLY ENGINEERED PLANTS**

**1. NAME, ADDRESS, TELEPHONE, AND EMAIL OF APPLICANT**

**Name:** PII  
**Position:** PII  
**Organization:** betaseed  
**Organization Unique ID:** BTS  
**Address:** 1788 Marschall Road  
P.O. Box 195  
Shakopee, MN 55379  
**County/Province:** Scott  
**Township/Island:**  
**Day Telephone:** PII  
**FAX:**  
**Alternate:** PII  
**Email 1:** PII betaseed.com  
**Email 2:**

**2. INTRODUCTION TYPE**

- Importation  
 Interstate Movement  
 Interstate Movement and Release  
 Release

**3. APPLICANT REFERENCE NUMBER**

BTS11-01-i-HT

**4. CONFIDENTIAL BUSINESS INFORMATION VERIFICATION (CBI)**Does this application contain CBI?  Yes  No**CBI Justification:**

The information claimed as confidential within this application includes personal, site and or molecular information. US data privacy law (and similar laws in other jurisdictions) protect individuals from the misuse of their personal information. The gene description category includes names and information about genes, promoters and expressed traits. The Freedom of Information Act ("FOIA"), 5 U.S.C. section 552, specifically exempts from release "trade secrets and commercial or financial information obtained from a person and privileged or confidential" ("Exemption 4"), 5 U.S.C. section 552(b)(4). Exemption 4 applies where the disclosure of information would be likely to cause substantial harm to the competitive position of the owner, or where, in the case of voluntarily submitted information, the submitter would be less likely in the future to share data with the agency voluntarily. Information on gene description and commercial development falls within this definition, and is the type of information accorded trade secret protection by the courts under Exemption 4 of the Freedom of Information Act. The release of information about the genes and promoters in the vectors will directly provide competitors with the knowledge of the precise genetic sequence - that KWS/Betaseed has found to be most desirable. If this information is disclosed, the competitors will have access to the structure of the KWS/Betaseed products, with the consequences outlined above.

**5. REGULATED ARTICLE**

**Scientific Name:** Beta vulgaris ssp. vulgaris  
**Common Name:** Sugarbeet  
**Cultivar and/or Breeding Line:** Elite lines derived from Beta vulgaris ssp. vulgaris

**6. PHENOTYPIC DESIGNATION**

**1) Phenotypic Designation Name:** Glyphosate resistant sugarbeet  
**Identifying Line(s):** H7-1  
**Construct(s):** PV-BVGT08  
**Mode of Transformation:** Disarmed Agrobacterium tumefaciens transformation

**Phenotype(s)**

HT - glyphosate tolerance

**Genotype(s)**

Gene of inter

Promoter: [redacted] from [redacted]

Terminator: [redacted] from [redacted].

**7. INTRODUCTION**

Point of Origin

<u>Location Name &amp; Description</u>	<u>Location Address</u>	<u>Contact(s)</u>
1) [ ] - [ ]	[ ] [ ] [ ] [ ] [ Canada ], [ ] <b>County:</b> Alberta	1) Mr. [ ] [ ] [ ] [ ] [ ] Linn [ ], Oregon [ ] USA <b>Day Telephone:</b> [ ] <b>Alt. Telephone:</b> [ ] <b>Email 1:</b> [ & nbs p; ]

Destination

<u>Location Name &amp; Description</u>	<u>Location Address</u>	<u>Contact(s)</u>
1) [ ] - [ ]	[ ] [ ] [ ], Oregon [ ] <b>County:</b> Linn <b>Proposed Start Date:</b> 02/01/2011 <b>Proposed End Date:</b> 02/01/2012 <b>Quantity:</b> [ ]  [ ] lbs seed, whole plants, roots and leaves to/from each site	1) Mr. [ ] [ ] [ ] [ ] [ ] Linn [ ], Oregon [ ] USA <b>Day Telephone:</b> [ ] <b>Alt. Telephone:</b> [ ] <b>Email 1:</b> [ & nbs p; ]

**8. ADDITIONAL INFORMATION**

I, **PII** certify that the regulated article will be introduced in accordance with the eligibility criteria and the performance standards set forth in 7 CFR 340.3. The above information is true to the best of our knowledge.

I acknowledge this is not an application to move or import select agents, the genes expressing select agents, or the toxins made by the select agents, as described in 9 CFR 121.

If there are any changes to the information disclosed in this application, I will contact APHIS.

**9. SIGNATURE OF RESPONSIBLE PERSON**

**10. DATE**

**PII**

January 17, 2011